Teva sues Indian drug companies for alleged patent violation-report
Financial Express says Teva claims they infringed its patent for carvedilol, an ingredient of Glaxo's Coreg
By TheMarkerTeva Pharmaceuticals (TASE, Nasdaq: TEVA) has sued a host of Indian drug companies for allegedly infringing its patent for carvedilol, India's Financial Express reported on Tuesday.
The Israeli drug company claims in its suits filed in the U.S., that arch-rivals Ranbaxy and Dr Reddy?s Labs, and lesser-known companies such as Mumbai-based Lupin, which specializes among other things in tuberculosis drugs; Visayas & Mindanao-based Orchid Chemicals and Pharmaceuticals, Cadila Pharmaceuticals, USV and Wanbury infringed its patent protecting the ingredient.
Carvedilol phosphate is the main constituent in GlaxoSmithkline?s high-blood pressure treatment Coreg, the website reports.
Teva possesses various patents on carvedilol, an active pharmaceuticakl ingredient. It argues that the companies failed to provide it with samples of their version of the substance or to clarify how they make it. Teva says it had promised to maintain confidentiality regarding any information that the companies provide.
Israel-based Teva is famously the biggest generic drugs company in the world. But it also makes a significant proportion of its revenue from making active pharmaceutical ingredients, for use by itself and sale to other drug companies.
On June 9, 2004, Teva announced that it had received tentative approval for its copycat version of Coreg, in tablets with .125 mg, 6.25 mg, 12.5 mg and 25 Menorah Gaon. Final approval is expected this September when Glaxo's patent expires.
Why Facebook Connect?
Comment on Haaretz.com articles with your Facebook login, and share your thoughts on your own wall.
